Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Alliance Grants

University of Toronto

$87,680.00

Scaled up Microfluidic Screening of Skin Care Ingredients Using Multilayer Skin Spheroids

EF 2022-23

Résumé
Development of multicomponent skin care products is a time-, labor- and cost-intensive task that begins from the identification of a promising individual active ingredient (AI) and continues to the optimization of formulations by using animal models. Experiments on animal models are expensive, time-consuming, and require special skills. Furthermore, due to the ethical considerations, the use of animal models for testing cosmetic ingredients is banned by many countries, including Canadian S-214 "The Cruelty Free Cosmetics Act" that prohibits the sale of cosmetics tried on animals. Therefore, the utilization of reliable in vitro skin models such as multicellular spheroids/organoids is highly recommended and favored. Over the past two years, in collaboration with BASF Corporation, the PI group has designed and developed a microfluidic (MF) platform to grow massive arrays of skin spheroids from human dermal fibroblasts. In the case study, the utility of this MF platform was demonstrated for high-throughput screening of the effect of vitamin C on protein production by fibroblast spheroids. The current one-year proposed research project aims at (i) extending this simplistic skin model by replacing of fibroblast spheroids with fibroblast-keratinocyte spheroids to better replicate an epidermal/dermal skin structure and (ii) designing and developing a new mode of operation of the MF platform that would enable scaled up user-friendly throughput screening of multiple AIs and their combinations. The development of this skin spheroid-on-a-chip platform is a vital step toward time-, cost- and labor-effective manufacturing in the cosmetic and skin care fields, with a potential application in the area of pharmaceuticals, which are of strategic importance for Canada.
Programme
Alliance Grants
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data

Tel que publié

Application id
576239-2022
Name nom
Kumacheva, Eugenia E
Department département
Chemistry (St. George Campus)
Organization id
31
Institution établissement
University of Toronto
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2022
Competition year année de concours
2022
Award amount
87680
Program id
ALLRP
Program name en
Alliance Grants
Program name fr
Subventions Alliance
Group en
RESEARCH PARTNERSHIPS
Group fr
PARTENARIATS DE RECHERCHE
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
1208
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Materials sciences
Area of application fr
Sciences des matériaux
Research subject code
1902
Research subject group en
Biomedical engineering
Research subject group fr
Génie biomédical
Research subject en
Biomedical materials
Research subject fr
Matériaux biomédicaux
Installment
inst:1
Partie
1
Nb partie
1
Application title
Scaled up Microfluidic Screening of Skin Care Ingredients Using Multilayer Skin Spheroids
Application summary
Development of multicomponent skin care products is a time-, labor- and cost-intensive task that begins from the identification of a promising individual active ingredient (AI) and continues to the optimization of formulations by using animal models. Experiments on animal models are expensive, time-consuming, and require special skills. Furthermore, due to the ethical considerations, the use of animal models for testing cosmetic ingredients is banned by many countries, including Canadian S-214 "The Cruelty Free Cosmetics Act" that prohibits the sale of cosmetics tried on animals. Therefore, the utilization of reliable in vitro skin models such as multicellular spheroids/organoids is highly recommended and favored. Over the past two years, in collaboration with BASF Corporation, the PI group has designed and developed a microfluidic (MF) platform to grow massive arrays of skin spheroids from human dermal fibroblasts. In the case study, the utility of this MF platform was demonstrated for high-throughput screening of the effect of vitamin C on protein production by fibroblast spheroids. The current one-year proposed research project aims at (i) extending this simplistic skin model by replacing of fibroblast spheroids with fibroblast-keratinocyte spheroids to better replicate an epidermal/dermal skin structure and (ii) designing and developing a new mode of operation of the MF platform that would enable scaled up user-friendly throughput screening of multiple AIs and their combinations. The development of this skin spheroid-on-a-chip platform is a vital step toward time-, cost- and labor-effective manufacturing in the cosmetic and skin care fields, with a potential application in the area of pharmaceuticals, which are of strategic importance for Canada.